Evidence map›Paper›PMID 25177235›Full record

ReviewRadiology and oncology2014

The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma.

Carmelo Caldarella, Barbara Muoio, Maria Antonietta Isgrò, Emilio Porfiri, Giorgio Treglia, Luca Giovanella

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Radiology and oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2015
    Trial
  5. Review
  6. Review
  7. Review
  8. [European journal of nuclear medicine and molecular imaging · 2021
    Article
  9. Review
  10. Review
  11. Review
  12. Annals of translational medicine · 2019
    Article
  13. Review
  14. Article
  15. Nagoya journal of medical science · 2017
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma.Indian journal of urology : IJU : journal of the Urological Society of India
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 4 countries.

Carmelo CaldarellaInstitute of Nuclear Medicine, PET/CT Center, Catholic University, Rome, Italy.
Barbara MuoioSchool of Medicine, Catholic University, Rome, Italy.
Maria Antonietta IsgròInstitute of Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy.
Emilio PorfiriSchool of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
Giorgio TregliaDepartment of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Luca GiovanellaDepartment of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Institute of Oncology Research · CHUniversità Cattolica del Sacro Cuore · ITCatholic University of America · USUniversity of Birmingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPositron emission tomography-computed tomography (PET-CT) using fluorodeoxyglucose (FDG) is increasingly used in the evaluation of patients with advanced renal cell carcinoma (RCC), primarily for staging purposes. The aim of this paper is to perform a systematic review about the usefulness of PET-CT using FDG in response assessment after treatment with tyrosine-kinase inhibitors (TKIs) in patients with advanced RCC. MATERIALS AND

methodsThe scientific literature about the role of PET-CT using FDG in the assessment of response to treatment with TKIs in patients affected by advanced RCC was systematically reviewed.

resultsSeven studies about the role of PET-CT using FDG in the response assessment after treatment with TKIs (essentially sunitinib and sorafenib) in advanced RCC were retrieved in full-text and analysed, to determine the predictive role of this morpho-functional imaging method on patient outcome.

conclusionsTo date, the role of PET-CT using FDG in evaluating the response to TKIs in metastatic RCC patients is still not well defined, partly due to heterogeneity of available studies; however, PET-CT reveals potential role for the selection of patients undergoing therapy with TKIs. The use of contrast-enhanced PET-CT appears to be promising for a "multi-dimensional" evaluation of treatment response in these patients.

Indexed as

advanced renal cell carcinomafluorodeoxyglucosepositron emission tomographyresponse to treatmenttyrosine-kinase inhibitors

Identifiers

PMID25177235
PMCPMC4110077
OpenAlexW2049267527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.